EcoR1 Capital’s Achillion Pharmaceuticals ACHN Stock Holding History

EcoR1 Capital’s Portfolio ACHN Stock Details ACHN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1,564,080	Closed	-$5.76M	–	68
2018 Q3	$5.76M	Sell	1,564,080 -2,323,327	-60%	-$6.92M	0.52%	34
2018 Q2	$11M	Buy	3,887,407 +219,100	+6%	+$746K	1.05%	24
2018 Q1	$13.6M	Buy	3,668,307 +1,827,582	+99%	+$5.98M	1.36%	19
2017 Q4	$5.3M	Buy	+1,840,725	New	+$6.69M	0.6%	22
2017 Q3	–	Sell	-742,835	Closed	-$3.41M	–	50
2017 Q2	$3.41M	Buy	+742,835	New	+$2.99M	0.61%	24

Other funds holding ACHN

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

MCO

MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

EcoR1 Capital's ACHN Position: Q4 2018 in Review

EcoR1 Capital sold out of Achillion Pharmaceuticals (ACHN) in Q4 2018, closing a stake of 1,564,080 shares — an estimated $5.76M sold.

EcoR1 Capital first reported a position in ACHN in Q2 2017 and held it in 5 quarters. The position peaked at $13.6M in Q1 2018. 121 funds tracked by Wall St. Rank hold ACHN as of Q4 2018.

EcoR1 Capital reported no remaining Achillion Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
EcoR1 Capital sold 1,564,080 Achillion Pharmaceuticals shares in Q4 2018, an estimated $5.76M.
EcoR1 Capital first reported a position in Achillion Pharmaceuticals in Q2 2017 and held it in 5 quarters.
EcoR1 Capital's Achillion Pharmaceuticals position peaked at $13.6M in Q1 2018.
121 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q4 2018.

Based on EcoR1 Capital's 13F filing for Q4 2018, filed 14 Feb 2019.